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syndrome patientsDear Editor,
We read with great interest the paper by Chen et al,1 the
first of its kind that investigated the efficacy and safety of
ticagrelor versus clopidogrel in patients with acute coronary
syndrome (ACS) in Asia (including Taiwan) in a real-life
clinical setting. In their analysis, the authors reported that a
higher number of patients treated with ticagrelor experienced
dyspnea as compared with those patients treated with clopi-
dogrel in both overall (25.0% vs. 14.6%, p< 0.001) and
propensity-matched (21.0% vs. 11.6%, p¼ 0.01) cohorts.
Furthermore, they affirmed that the incidence of dyspnea-
related discontinuation of P2Y12 antagonist treatment tended
to be higher in the ticagrelor group by propensity score
matching. In particular, their study showed that when com-
pared with clopidogrel treatment, ticagrelor causes a fourfold
increase in the incidence of dyspnea and required dis-
continuation of a P2Y12 antagonist. During our intensive
pharmacovigilance activities in emergency departments (EDs),
we encountered several cases of dyspnea associated with
ticagrelor treatment. In particular, we observed a case of
severe paroxysmal nocturnal dyspnea developed in a post-
stenting 90-year-old man associated with the first use of
ticagrelor.2 We then conducted a retrospective cohort study in
the EDs of the Florence (Italy) metropolitan area to define the
occurrence rate of dyspnea leading to ED admission in ACS
for patients treated with ticagrelor. Among community-
dwelling patients who were prescribed ticagrelor from
2012e2014, the overall dyspnea occurrence was about 2%
(1.86%, 20/1073 patients). All cases of outpatient dyspnea
were severe and caused an ED admission. The median
time between the first prescription of ticagrelor and the onset
of dyspnea was 47 days (interquartile range: 10e185).3
Although the clinical data showed that ticagrelor treatment
is generally well-tolerated and discontinuation rates are com-
parable to those observed for clopidogrel,4,5 the Chen et al1
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setting) evaluated ticagrelor’s safety profile.6e8 Consistent
with the results of Chen et al1 and based on our pharmaco-
vigilance experience, what we observed for dyspnea might
happen for other adverse drug reactions (ADRs) related to
ticagrelor use. While randomized controlled trials (RCTs) are
preferable when evidence of treatment efficacy must be pro-
vided, circumstances become more complex when the risk of
ADRs needs to be assessed.9 The lack of ADR data from
RCTs is well-known; generally, RCTs often do not include a
large population sample or do not have adequate follow-up to
identify rare ADRs, and safety data quality is generally poor.
Considering the relevant differences between data derived
from RCTs and observational studies, as we observed in the
case of dyspnea from the platelet inhibition and patient out-
comes trial10 and the study by Chen et al1, we strongly agree
with the authors’ observations when they affirmed that the
discretion of a physician in a real-world setting should derive
from both observational and clinical evidence. In conclusion,
we also believe that further and larger observational studies
are needed to identify the real-world safety profile of tica-
grelor in ACS patients, in order to guarantee the clinician’s
best therapeutic choice.References
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